ECSP23088732A - Moduladores de trex1 - Google Patents

Moduladores de trex1

Info

Publication number
ECSP23088732A
ECSP23088732A ECSENADI202388732A ECDI202388732A ECSP23088732A EC SP23088732 A ECSP23088732 A EC SP23088732A EC SENADI202388732 A ECSENADI202388732 A EC SENADI202388732A EC DI202388732 A ECDI202388732 A EC DI202388732A EC SP23088732 A ECSP23088732 A EC SP23088732A
Authority
EC
Ecuador
Prior art keywords
trex1
modulators
compositions
compounds
variety
Prior art date
Application number
ECSENADI202388732A
Other languages
English (en)
Inventor
Aaron Coffin
Jonathan Wilson
Avinash Khanna
Julian Levell
Jennifer Rocnik
Mary-Margaret Zablocki
David Guerin
William Mcelroy
Original Assignee
Constellation Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Constellation Pharmaceuticals Inc filed Critical Constellation Pharmaceuticals Inc
Publication of ECSP23088732A publication Critical patent/ECSP23088732A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Amplifiers (AREA)

Abstract

Compuestos de Fórmula (I): y sales farmacéuticamente aceptables y composiciones de los mismos, que son útiles para el tratamiento de una variedad de condiciones asociadas con la TREX1.
ECSENADI202388732A 2021-04-26 2023-11-23 Moduladores de trex1 ECSP23088732A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163179723P 2021-04-26 2021-04-26

Publications (1)

Publication Number Publication Date
ECSP23088732A true ECSP23088732A (es) 2024-02-29

Family

ID=81598085

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202388732A ECSP23088732A (es) 2021-04-26 2023-11-23 Moduladores de trex1

Country Status (20)

Country Link
US (1) US20240246946A1 (es)
EP (1) EP4330254A1 (es)
JP (1) JP2024517715A (es)
KR (1) KR20240028979A (es)
CN (1) CN117545754A (es)
AR (1) AR125448A1 (es)
AU (1) AU2022264711A1 (es)
BR (1) BR112023022298A2 (es)
CA (1) CA3216752A1 (es)
CL (1) CL2023003168A1 (es)
CO (1) CO2023015732A2 (es)
CR (1) CR20230542A (es)
DO (1) DOP2023000236A (es)
EC (1) ECSP23088732A (es)
IL (1) IL308016A (es)
JO (1) JOP20230271A1 (es)
MX (1) MX2023012678A (es)
PE (1) PE20242223A1 (es)
TW (1) TW202309019A (es)
WO (1) WO2022232004A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024061300A1 (en) * 2022-09-22 2024-03-28 Insilico Medicine Ip Limited Inhibitors of trex1 and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9328075B2 (en) * 2011-05-05 2016-05-03 St. Jude Children's Research Hospital Pyrimidinone compounds and methods for treating influenza
MA54386B1 (fr) * 2018-12-06 2023-08-31 Constellation Pharmaceuticals Inc Modulateurs de trex1
WO2021016317A1 (en) * 2019-07-23 2021-01-28 Constellation Pharmaceuticals, Inc. Modulators of trex1

Also Published As

Publication number Publication date
EP4330254A1 (en) 2024-03-06
PE20242223A1 (es) 2024-11-19
BR112023022298A2 (pt) 2023-12-26
AR125448A1 (es) 2023-07-19
US20240246946A1 (en) 2024-07-25
JP2024517715A (ja) 2024-04-23
CL2023003168A1 (es) 2024-04-12
JOP20230271A1 (ar) 2023-10-26
WO2022232004A1 (en) 2022-11-03
CA3216752A1 (en) 2022-11-03
TW202309019A (zh) 2023-03-01
CN117545754A (zh) 2024-02-09
MX2023012678A (es) 2024-02-08
CO2023015732A2 (es) 2024-02-05
AU2022264711A1 (en) 2023-11-09
DOP2023000236A (es) 2024-02-29
CR20230542A (es) 2024-03-19
KR20240028979A (ko) 2024-03-05
IL308016A (en) 2023-12-01

Similar Documents

Publication Publication Date Title
CL2021001461A1 (es) Moduladores de trex1
CO2020014217A2 (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
MX2024012029A (es) Moduladores del transductor de señal y activador de la transcripción y usos de los mismos
CL2022003360A1 (es) Benzofurano, benzopirrol, benzotiofeno sustituidos y otros inhibidores del complemento estructuralmente relacionados (divisional de la solicitud 202002578)
CO2024012743A2 (es) Derivados de 6-oxodecahidropirrolo[1,2-a][1,5]diazocina y 6-oxodecahidro-4h-pirrolo[2,1-d][1,5]tiazocina como moduladores de stat3 y stat6 para el tratamiento de cáncer y condiciones inflamatorias
MX2021011606A (es) Compuestos dirigidos a prmt5.
PY1996328A (es) Compuestos de azalactam como inhibidores de hpk1
MX2020007947A (es) Inhibidores de erbb/btk.
DOP2016000017A (es) Nuevos compuestos tricíclicos
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
UY35617A (es) Inhibidores de la fosfatidilinositol 3-quinasa
MX2020009530A (es) Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa.
MX2024009943A (es) Inhibidores de arn helicasa dhx9 y usos de los mismos
ECSP22085221A (es) Pirrolopirimidinaminas como inhibidores del sistema del complemento
CL2024001346A1 (es) Agonistas inversos del pparg y usos de los mismos
MX2022004168A (es) Compuestos aromaticos de arilmetileno a manera de bloqueadores del canal de potasio kv1.3.
ECSP23091202A (es) Moduladores de trex1
MX2022007623A (es) Combinaciones.
CL2020003380A1 (es) Compuestos que aumentan la actividad del proteosoma.
CL2025002615A1 (es) Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno
ECSP23088732A (es) Moduladores de trex1
MX2024010402A (es) Inhibidores de proteinas de union a emopamilo y usos de estos
UY40025A (es) Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno, y composiciones far
CO2025004559A2 (es) Compuestos de sulfoximina como inhibidores de la histona desacetilasa 6, y composición farmacéutica que comprende los mismos
AR128426A1 (es) Compuestos heterocíclicos y métodos de uso